Top

World Journal of Urology

Published in:

01-06-2009 | Topic Paper

The novel use of intravesical docetaxel for the treatment of non-muscle invasive bladder cancer refractory to BCG therapy: a single institution experience

Authors: LaMont J. Barlow, James M. McKiernan, Mitchell C. Benson

Published in: World Journal of Urology | Issue 3/2009

Abstract

Objectives

Since the success of our Phase I trial of intravesical docetaxel for treatment-refractory non-muscle invasive bladder cancer (NMIBC), we have found this agent to be a favorable alternative for BCG-refractory patients unable or unwilling to undergo cystectomy. This study analyzes the safety and efficacy of intravesical docetaxel in a larger patient population with extended follow-up.

Methods

A retrospective analysis of all patients who received salvage intravesical docetaxel at our institution was conducted, including 18 patients treated during the Phase I trial and 15 patients treated after the trial’s completion. Toxicity, efficacy and recurrence-free survival were analyzed.

Results

Thirty-three patients with refractory NMIBC received salvage intravesical docetaxel therapy between 2003 and 2008 at a single institution. Twenty of thirty-three (61%) patients had a complete response (CR) after six weekly induction treatments. Ten patients with CRs were given maintenance docetaxel therapy, and one patient received maintenance BCG and interferon. With a median follow-up of 29 months, 1 and 2-year recurrence-free survival rates were and 45 and 32%, respectively. Twelve of thirty-three patients (36%) had Grade 1 or 2 local toxicities. No patients experienced Grade 3 or 4 toxicities.

Conclusions

Docetaxel is a promising intravesical agent with minimal toxicity and significant efficacy and durability for the management of BCG-refractory NMIBC.

Epstein JI, Amin MB, Reuter VR et al (1998) The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder Bladder Consensus Conference Committee. Am J Surg Pathol 22:1435. doi:10.1097/00000478-199812000-00001 PubMedCrossRef

Morales A, Eidinger D, Bruce AW (1976) Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 116:180PubMed

Brosman SA (1982) Experience with bacillus Calmette-Guerin in patients with superficial bladder carcinoma. J Urol 128:27PubMed

Smith JA Jr, Labasky RF, Cockett AT et al (1999) Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS). The American Urological Association. J Urol 162:1697. doi:10.1016/S0022-5347(05)68208-0

Catalona WJ, Hudson MA, Gillen DP et al (1987) Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. J Urol 137:220PubMed

McKiernan JM, Masson P, Murphy AM et al (2006) Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy. J Clin Oncol 24:3075. doi:10.1200/JCO.2005.03.1161 PubMedCrossRef

de Wit R, Kruit WH, Stoter G et al (1998) Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a Phase II study in non-chemotherapy-pretreated patients. Br J Cancer 78:1342PubMed

Chan S, Friedrichs K, Noel D et al (1999) Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 17:2341PubMed

Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502. doi:10.1056/NEJMoa040720 PubMedCrossRef

10.

Calabro F, Sternberg CN (2002) New drugs and new approaches for the treatment of metastatic urothelial cancer. World J Urol 20:158PubMed

11.

Lamm DL, Blumenstein BA, Crissman JD et al (2000) Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 163:1124. doi:10.1016/S0022-5347(05)67707-5 PubMedCrossRef

12.

Friedrich MG, Pichlmeier U, Schwaibold H et al (2007) Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with bacillus Calmette-Guerin (BCG) in patients with non-muscle-invasive bladder carcinoma. Eur Urol 52:1123. doi:10.1016/j.eururo.2007.02.063 PubMedCrossRef

13.

Kaplan EL, Meier P (1958) Nonparametric estimation of incomplete observations. J Am Stat Assoc 53:457. doi:10.2307/2281868 CrossRef

14.

Jones JS, Campbell SC (2006) Non-muscle-invasive bladder cancer (Ta, T1, and CIS). In: Wein AJ, Kavoussi LR, Novick AC et al (eds) Campbell-Welsh urology, vol 3, Saunders, Philadelphia. pp 2447–2467

15.

Herr HW, Wartinger DD, Fair WR et al (1992) Bacillus Calmette-Guerin therapy for superficial bladder cancer: a 10-year followup. J Urol 147:1020PubMed

16.

Palapattu GS, Haisfield-Wolfe ME, Walker JM et al (2004) Assessment of perioperative psychological distress in patients undergoing radical cystectomy for bladder cancer. J Urol 172:1814. doi:10.1097/01.ju.0000141245.08456.1a PubMedCrossRef

17.

Crawford ED (2002) Intravesical therapy for superficial cancer: need for more options. J Clin Oncol 20:3185PubMed

18.

Babaian RJ, Smith DB (1991) Effect of ileal conduit on patients’ activities following radical cystectomy. Urology 37:33. doi:10.1016/0090-4295(91)80073-G PubMedCrossRef

19.

Huncharek M, McGarry R, Kupelnick B (2001) Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis. Anticancer Res 21:765PubMed

20.

Kurth K, Tunn U, Ay R et al (1997) Adjuvant chemotherapy for superficial transitional cell bladder carcinoma: long-term results of a European Organization for Research and Treatment of Cancer randomized trial comparing doxorubicin, ethoglucid and transurethral resection alone. J Urol 158:378. doi:10.1016/S0022-5347(01)64484-7 PubMedCrossRef

21.

Greenberg RE, Bahnson RR, Wood D et al (1997) Initial report on intravesical administration of N-trifluoroacetyladriamycin-14-valerate (AD 32) to patients with refractory superficial transitional cell carcinoma of the urinary bladder. Urology 49:471. doi:10.1016/S0090-4295(96)00621-8 PubMedCrossRef

22.

Thrasher JB, Crawford ED (1992) Complications of intravesical chemotherapy. Urol Clin North Am 19:529PubMed

23.

Witjes JA, van der Heijden AG, Vriesema JL et al (2004) Intravesical gemcitabine: a phase and pharmacokinetic study. Eur Urol 45:182. doi:10.1016/j.eururo.2003.09.014 PubMedCrossRef

24.

Dalbagni G, Russo P, Bochner B et al (2006) Phase II trial of intravesical gemcitabine in bacille Calmette-Guerin-refractory transitional cell carcinoma of the bladder. J Clin Oncol 24:2729. doi:10.1200/JCO.2005.05.2720 PubMedCrossRef

25.

Song D, Wientjes MG, Au JL (1997) Bladder tissue pharmacokinetics of intravesical taxol. Cancer Chemother Pharmacol 40:285. doi:10.1007/s002800050660 PubMedCrossRef

26.

Nabi G, Greene D, O’Donnell MO (2004) Suspicious urinary cytology with negative evaluation for malignancy in the diagnostic investigation of haematuria: how to follow up? J Clin Pathol 57:365. doi:10.1136/jcp.2003.009696 PubMedCrossRef

27.

Herr HW, Cookson MS, Soloway SM (1996) Upper tract tumors in patients with primary bladder cancer followed for 15 years. J Urol 156:1286. doi:10.1016/S0022-5347(01)65570-8 PubMedCrossRef

Title: The novel use of intravesical docetaxel for the treatment of non-muscle invasive bladder cancer refractory to BCG therapy: a single institution experience
Authors: LaMont J. Barlow
James M. McKiernan
Mitchell C. Benson
Publication date: 01-06-2009
Publisher: Springer-Verlag
Published in: World Journal of Urology / Issue 3/2009
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-009-0377-1

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

The novel use of intravesical docetaxel for the treatment of non-muscle invasive bladder cancer refractory to BCG therapy: a single institution experience

Abstract

Objectives

Methods

Results

Conclusions

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Objectives

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2009

A morphological evaluation of botulinum neurotoxin A injections into the detrusor muscle using magnetic resonance imaging

Updates in intravesical electromotive drug administration® of mitomycin-C for non-muscle invasive bladder cancer

Application of new technology in bladder cancer diagnosis and treatment

Topic issue on new treatments in bladder cancer

The value of newborn urinary proteome analysis in the evaluation and management of ureteropelvic junction obstruction: a cost-effectiveness study

Two-year follow-up of the phase II marker lesion study of intravesical apaziquone for patients with non-muscle invasive bladder cancer